DiaMedica Therapeutics Prepares to Showcase Innovations at Craig-Hallum Conference 2024

DiaMedica Therapeutics Sets Stage for Innovative Treatments at Upcoming Conference

DiaMedica Therapeutics Inc. engages in a critical endeavor aimed at revolutionizing the treatment landscape for severe ischemic diseases. The company prepares to showcase its advancements during the 15th Annual Craig-Hallum Alpha Select Conference, taking place on November 19, 2024, in New York City. Here, DiaMedica's management will have the opportunity to connect with investors and stakeholders, underscoring its commitment to addressing conditions such as acute ischemic stroke and preeclampsia through innovative pharmaceutical solutions. The engagement at this conference represents a key moment for DiaMedica, allowing it to highlight its cutting-edge research and the potential impact of its lead candidate, DM199.

DM199 is a pioneering recombinant form of the KLK1 protein, which has demonstrated therapeutic efficacy in Asian markets for treating acute ischemic stroke, preeclampsia, and other vascular diseases. With the significant medical burden posed by these conditions, DiaMedica positions itself at the forefront of biopharmaceutical innovation. The company aims to not only enhance patient outcomes but also improve the overall quality of life for those affected by debilitating ischemic diseases. As it moves forward, DiaMedica remains focused on leveraging its research capabilities to offer novel treatments that meet critical unmet medical needs.

In addition to its conference participation, DiaMedica recently announced major updates regarding its ReMEDy2 trial protocol. Following constructive discussions with trial investigators and stroke experts, the company has broadened the trial population to include patients who do not respond to commonly used thrombolytic treatments. This strategic modification aims to enhance the statistical validity of the trial results and potentially shorten the timeline for bringing DM199 to market. By capturing a more diverse patient group, including those with persistent neurological deficits post-thrombolytic therapy, DiaMedica anticipates bolstering the primary outcome measures of the trial, ultimately increasing the chances of success for its therapeutic interventions.

DiaMedica Therapeutics continues to prioritize its mission of developing innovative treatments for serious ischemic conditions. The upcoming Craig-Hallum conference serves as a pivotal platform for the company to engage with the investment community and discuss its advancements in the field. Concurrently, the enhancements to the ReMEDy2 trial protocol reflect a proactive approach to clinical research, demonstrating DiaMedica's commitment to refining its methodologies and optimizing patient outcomes. For more information on DiaMedica's initiatives, interested parties can visit the company’s website at www.diamedica.com.